Top

The European Journal of Health Economics

Published in:

01-09-2006 | Original Papers

The costs of schizophrenia in Spain

Authors: Juan Oliva-Moreno, Julio López-Bastida, Rubén Osuna-Guerrero, Angel Luis Montejo-González, Beatriz Duque-González

Published in: The European Journal of Health Economics | Issue 3/2006

Abstract

This study estimated the economic impact of schizophrenia-related direct costs (medical and nonmedical costs) in Spain. Direct medical costs (hospitalizations, outpatient consultations, drug costs) and direct nonmedical costs (costs of informal care) were estimated based on prevalence costs for 2002. The total costs of schizophrenia were estimated at €1,970.8 million; direct medical costs accounted for 53% and informal care costs 47%. Despite having implemented a conservative approach, the health care costs associated with schizophrenia account for 2.7% of total public health care expenditure in Spain. The sum of medical and nonmedical costs give us a better definition of the magnitude of the problem in Spain as well as contributing to helping make the debate on this issue more transparent.

Anonymous (1993) Report on choices in health care. Ministry of Health, Welfare and Cultural Affairs: The Netherlands

Anonymous (2001) Estadísticas de establecimientos sanitarios con régimen de internado. Ministry of Health Care and Consumer Affairs: Madrid

Anonymous (2002) Información terapéutica del sistema nacional de salud, vol 26, no 2. General Directorate of Pharmacy, Ministry of Health Care and Consumer Affairs: Madrid

Anonymous (2002) Información terapéutica del sistema nacional de salud. vol 28, no 2–. General Directorate of Pharmacy, Ministry of Health Care and Consumer Affairs: Madrid

Anonymous (2003) Estudio Depresión Monitor. TNS healthcare

Baca E, Roca M, Varela C, on behalf of the ACE Group (2004) Prevalence of comorbidities in ambulatory schizophrenic patients treated with antipsychotics. Poster presented at the ECNP, Stockholm

Baca E, Roca M, Varela C, on behalf of the ACE Group (2004) Treatment profile of schizophrenic outpatients in Spain. Poster presented at the CINP, Paris

Berg B van den, Brouwer W, Koopmanschap M (2004) Economic valuation of informal care: an overview of methods and applications. Eur J Health Econ 5: 36–45CrossRefPubMed

Carr VJ, Neil AL, Halpin SA et al. (2003) Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 37: 31–40CrossRefPubMed

10.

Clark RE, Xie H, Adarhi-Meija AM, Sergupta A (2001) Substitution between formal and informal care for persons with severe mental illness and substance use disorders. J Ment Health Policy Econ 4: 123–132PubMed

11.

Davis LM, Drummond MF (1994) Economics and schizophrenia: the real cost. Br J Psychiatry 165: 18–21

12.

Díaz Berenguer JA, López Cabañas A, Cabeza Mora A (nd) Área técnica de la gerencia de atención primaria del Áreas de salud de Gran Canarias. Canary Islands Health Service

13.

Durán MA (2002) Los costes invisibles de la enfermedad. Fundación BBVA: Bilbao

14.

Evers SMAA, Ament AJHA (1995) Costs of schizophrenia in The Netherlands. Schizophr Bull 21: 141–153PubMed

15.

Foldemo A, Gullberg M, Ek AC, Bogren L (2005) Quality of life and burden in parents of outpatients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 40: 133–138CrossRefPubMed

16.

Frank RG, Berndt ER, Busch AB, Lehman AF (2003) Quality-constant price indexes for the ongoing treatment of schizophrenia: an exploratory study. NBER working paper no 10022

17.

Garattini L, Barbui C, Clemente R et al., on behalf of the Study Group SCORE (2004) Direct costs of schizophrenia and related disorders in Italy community mental health services: a multicenter, prospective 1-year follow up study. Schizophr Bull 30: 295–302PubMed

18.

Gisbert R, Brosa M, Figueras M et al. (1998) El coste de la enfermedad en España: el coste de las enfermedades cardiovasculares. Merck Sharp & Dohme: Madrid

19.

Goeree R, O’Brien BJ, Goering P et al. (1999) The economic burden of schizophrenia in Canada. Can J Psychiatry 44: 464–472PubMed

20.

Goeree R, Farahati F, Burke N et al. (2005) The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 21: 2017–2028CrossRefPubMed

21.

Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press: New York

22.

Greenhalgh J, Knight C, Hind D et al. (2005) Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 9: 1–170

23.

Guest JF, Cookson RF (1999) Cost of schizophrenia to U.K. society. Pharmacoeconomics 15: 597–610PubMed

24.

Haro JM, Salvador-Carrulla L, Cabases J et al. (1998) Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry 173: 334–340PubMed

25.

Hodgson TA, Meiners MR (1982) Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Q 60: 429–491

26.

Johnstone EC, Frith CD, Leary J et al. (1991) Background, method and general description of the sample. Br J Psychiatry 159 [Suppl 13]: 43–46

27.

Kaplan-Sadock (2004) Sinopsis de psiquiatría, 9th edn. Waverly Hispánica: Madrid

28.

Knapp M (1997) Costs of schizophrenia. Br J Psychiatry 171: 509–515PubMed

29.

Loosbrock DL, Zhao Z, Johnstone BM, Morris LS (2003) Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ 2003 6: 67–75

30.

Magliano L, Fadden G, Madianos M et al. (1998) Burden on the families of patients with schizophrenia: results of the BIOMED I study. Soc Psychiatry Psychiatr Epidemiol 33: 405–412CrossRefPubMed

31.

Martínez A, Nadal S, Beperet M, Mendioroz P and the Grupo Psicot (2000) Sobrecarga de los cuidados familiares de pacientes con esquizofrenia: factores determinantes. Anal Sis San Navarra 23: 101–110

32.

Mata I, Beperet M, Madoz V and the grupo Psicost (2000) Prevalencia e incidencia de la esquizofrenia en Navarra. Anal Sis San Navarra 23 [Suppl 1]: 29–36

33.

Max W, Rice DP, Mackenzie EJ (1990) The lifetime cost of injury. Inquiry 27: 332–343PubMed

34.

Montejo AL, Majadas S and the Grupo GEOPTE (2006) Análisis de los patrones de prescripción de antipsicóticos en Psiquiatría. Actas Esp Psiquiatr (in press)

35.

Oliva J, Lobo F, Molina B, Monereo S (2004) Direct health care costs of diabetic patients in Spain. Diabetes Care 27: 2616–2621PubMed

36.

Oliva J, Lobo F, López-Bastida J et al. (2005) Indirect costs of cervical and breast cancer in Spain. Eur J Health Econ 6: 309–313CrossRefPubMed

37.

Pang F (2002) Design, analysis and presentation of multinational economic studies; the need for guidance. Pharmacoeconomics 20: 75–90CrossRefPubMed

38.

Rice D, Miller LS (1996) The economic burden of schizophrenia: conceptual and methodological issues and costs estimates. In: Moscarelli M, Rupp A and Sartorius N (eds) Handbook of mental health economics and health policy, vol 1. Wiley: Chichester

39.

Robinson JC (1986) Philosophical origins of the economic valuation of life. Milbank Q 64: 133–155PubMed

40.

Rouillon F, Toumi M, Dansette GY et al. (1997) Some aspects of the cost of squizophrenia in France. Pharmacoeconomics 11: 578–594PubMed

41.

Salvador-Carulla L, Haro JM, Cabases J et al. (1999) Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in north-east Spain. PSICOST Group. Acta Psychiatr Scand 100: 335–343PubMed

42.

SEPB, SEMERGEN and SEP (2003) Uso y seguimiento del tratamiento con antidepresivos en atención primaria en España. Scientific Comunication Management: Madrid

43.

Sainsbury Centre for Mental Health (2003) The economic and social costs of mental illness. Sainsbury Centre for Mental Health: London

44.

Vázquez-Barquero JL, Diez Manrique JF, Pena C et al. (1987) A community mental health survey in Cantabria: a general description of morbidity. Psychol Med 17: 227–241PubMed

45.

Vos T, Haby MM, Magnus A et al. (2005) Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Aust N Z J Psychiatry 39: 701–712CrossRefPubMed

46.

Wu EQ, Birnbaum HG, Shi L et al. (2005) The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66: 1122–1129PubMed

47.

Wyatt RJ, Henter I, Leary MC, Taylor E (1995) An economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol 30: 196–205PubMed

Title: The costs of schizophrenia in Spain
Authors: Juan Oliva-Moreno
Julio López-Bastida
Rubén Osuna-Guerrero
Angel Luis Montejo-González
Beatriz Duque-González
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 3/2006
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-006-0350-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The costs of schizophrenia in Spain

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2006

Test-retest reliability of willingness to pay

Health care in the CIS countries

Problems and costs associated with alcohol and drug abuse in emergency medicine

Determinants of household health expenditure on western institutional health care

Price regulation and generic competition in the pharmaceutical market

Nonmedical economic consequences attributable to visual impairment